Aprea Therapeutics, Inc. (APRE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The company has shifted its primary focus from its previous p53 reactivator program (APR-246) to two core clinical programs acquired from Atrin Pharmaceuticals: ATRN-119 (an oral ATR inhibitor) and APR-1051 (an oral WEE1 inhibitor). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Grant Revenue | $354,621 | $319,468 | $1,296,764 | $569,156 |
| Total Operating Expenses | $4,451,637 | $3,842,318 | $12,390,374 | $12,366,190 |
| Net Loss | $(3,783,769) | $(3,204,515) | $(10,063,912) | $(10,843,502) |
| Net Loss Per Share (Basic/Diluted) | $(0.64) | $(0.86) | $(1.88) | $(3.03) |
| Cash and Cash Equivalents (Sept 30, 2024) | $26,249,625 | |||
| Accumulated Deficit (Sept 30, 2024) | $(318,147,073) | |||
| Net Cash Used in Operating Activities (YTD) | $(10,045,814) | $(8,437,950) | ||
| Net Cash Provided by Financing Activities (YTD) | $14,687,490 | $5,139,990 |
Material Changes vs. Prior Period
- Revenue: Grant revenue increased by approximately 11% in Q3 2024 compared to Q3 2023, and by 128% on a year-to-date basis, primarily driven by grants from the National Cancer Institute (NCI).
- Operating Expenses: Total operating expenses increased by 16% in Q3 2024 compared to the prior year quarter.
- R&D Expenses: Increased by $723,796 (34%) in Q3 2024. This was driven by a $1.0 million increase in costs for the ABOYA-119 clinical trial (ATRN-119), partially offset by a decrease in costs for APR-1051 IND-enabling studies.
- G&A Expenses: Decreased by $114,477 (7%) in Q3 2024, primarily due to lower insurance costs.
- Financing Activity: In March 2024, the company completed a private placement raising approximately $16.0 million in gross proceeds (net of ~$1.3 million in costs) through the sale of common stock, pre-funded warrants, and tranche A and B warrants. This significantly improved liquidity compared to the prior year period.
- Net Loss: The net loss for the nine months ended September 30, 2024, decreased by approximately $780,000 compared to the same period in 2023, despite higher R&D spend, due to increased grant revenue and lower G&A expenses (driven by severance costs in the prior year).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes the cash balance of approximately $26.2 million as of September 30, 2024, is sufficient to fund operating expenses and capital expenditures for at least twelve months from the date of the filing. The company expects to incur significant losses for the foreseeable future.
- Clinical Progress:
- ATRN-119: The Phase 1/2a ABOYA-119 trial is ongoing. The first five dose cohorts are complete, with the sixth enrolling. The protocol was amended to add BID dosing and a higher dose level. Potential efficacy data readout is anticipated in the second half of 2025.
- APR-1051: The Phase 1 ACESOT-1051 trial enrolled its first patient in Q2 2024. As of November 4, 2024, the company is enrolling cohort 4. Preliminary results indicate the drug is safe and well-tolerated. Open-label safety/efficacy data is expected in the first half of 2025.
- Risks and Contingencies:
- Capital Needs: The company will require substantial additional funding to continue operations and clinical development. Failure to raise capital could force delays or curtailment of programs.
- Development Risk: There is no assurance that clinical trials will be successful, that regulatory approval will be obtained, or that products will achieve commercial success.
- Third-Party Dependence: The company relies on third-party contract manufacturers for active pharmaceutical ingredients (API) and contract research organizations (CROs) for clinical trials.
- Intellectual Property: The chemical structure of the former lead candidate (eprenetapopt) is in the public domain, limiting patent protection to method-of-use and formulation claims.
Key Facts for Investor Verification
- Verify the runway estimate of 12 months based on the $26.2 million cash balance and current burn rate.
- Confirm the status of the March 2024 private placement warrants (Tranche A and B) and the specific price triggers ($14.58 and $18.225) required for their exercisability.
- Monitor the clinical trial enrollment rates for ABOYA-119 and ACESOT-1051, as delays could impact the anticipated 2025 data readouts.
- Review the grant revenue sustainability, as it currently offsets a small portion of operating expenses and is subject to government funding cycles.
- Assess the accumulated deficit of over $318 million and the company's ability to generate taxable income to utilize net operating loss carryforwards.